TianYu Bio-Technology(SH:603717) Xin Lang Cai Jing·2025-09-01 10:52Core Insights - Tianyu Bio (603717.SH) reported a total operating revenue of 412 million yuan for the first half of 2025, with a net profit attributable to shareholders of 10.82 million yuan, marking an increase of 4.59 million yuan compared to the same period last year, representing a year-on-year growth of 73.68% [1] - The company achieved a net cash inflow from operating activities of 89.83 million yuan, an increase of 31.90 million yuan from the same period last year, reflecting a year-on-year growth of 55.07% [1] Financial Performance - The latest debt-to-asset ratio stands at 75.62%, a decrease of 0.29 percentage points from the previous quarter [3] - The gross profit margin is reported at 14.64%, ranking 10th among disclosed peers [3] - Return on equity (ROE) is at 2.04%, an increase of 1.09 percentage points year-on-year, ranking 11th among disclosed peers [3] - The diluted earnings per share (EPS) is 0.04 yuan, an increase of 0.02 yuan compared to the same period last year, reflecting a year-on-year growth of 73.49% [3] - The total asset turnover ratio is 0.13 times, remaining stable compared to the same period last year, with a year-on-year increase of 2.57% [3] - The inventory turnover ratio is reported at 1.66 times [3] Shareholder Structure - The number of shareholders is 20,200, with the top ten shareholders holding a total of 115 million shares, accounting for 39.53% of the total share capital [3] - The top shareholders and their respective holdings are as follows: - T: 12.84% - Shi Dongwei: 11.15% - Shenzhen Zeyuan Private Securities Fund Management Co., Ltd.: 7.58% - Mao Shiqi: 2.67% - Ren Chao: 0.98% - Li Jixiang: 0.97% - Shanghai Luran Investment Management Co., Ltd.: 0.90% - Cha Qizuo: 0.89% - Ding Tai Sifang (Shenzhen) Private Fund Management Co., Ltd.: 0.80% - Barclays Bank PLC: 0.76% [3]